Skip to main content
. 2024 Jun 17;11(31):2400188. doi: 10.1002/advs.202400188

Figure 1.

Figure 1

Myogenesis in healthy and LGMD2B myobundles. A) Information and genotype for healthy (HLT, 1, 2, 3) and LGMD2B (A, B, C) hiPSC lines used in all presented studies. B) Schematic of experimental flow from iMPC generation to myobundle fabrication and assessment. C,D) Representative cross‐sections of C) healthy and D) LGMD2B myobundles stained for dysferlin and fast myosin heavy chain (F59). E–G) Representative whole‐myobundle staining of E) sarcomeric alpha‐actinin (SAA), F) myomesin‐2 (MyoM2), and G) titin. H,I) Representative cross‐sections for H) dystrophin staining used for quantification of myotube diameter I, n = 6 myobundles per donor). J) Representative western blots and quantified protein expression (normalized to β‐actin) of dysferlin and myosin heavy chain (MF20), (N = 4 differentiations per donor, 6 pooled myobundles per differentiation). **** P < 0.0001 vs. HLT. Data: mean ± SEM.